Metastatic Castration-resistant Prostate Cancer
Conditions
Keywords
metastatic castration-resistant prostate cancer, dendritic cell vaccine
Brief summary
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Detailed description
This is a single arm pilot study to evaluate the safety of delivering a dendritic cell vaccine in fifteen to twenty-four (n=15-24) adult patients diagnosed with prostate adenocarcinoma after novel androgen-deprived therapy and docetaxel chemotherapy failure. The study is constructed in a 3+3 design for three steps of dose escalation with rigorous and mandatory safety monitoring. Subjects received the vaccine at a dose of 5-15×10\^6 cells every two weeks for a total of 3 doses. A dose from cohort 1-3 is recommended for booster immunization every 4 weeks until disease progression or intolerance, to evaluate the safety and tolerability of the booster immunization of Prodencel. Subjects will be monitored for adverse events as dictated by CTCAE version 5.
Interventions
BIOLOGICALProdencel; an autologous dendritic cell therapeutic tumor vaccine
Subcutaneous injection, each injection point should not exceed 1ml.
Sponsors
Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical University
Shanghai Humantech Biotechnology Co. Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
： * Histologically prostate adenocarcinoma, exclusion of the initially diagnosed neuroendocrine or small-cell carcinoma. * Subjects with metastatic castration-resistant prostate cancer (mCRPC) who have failed novel androgen-deprived therapy and docetaxel chemotherapy. The previous antitumor treatment is ≥4 weeks prior to first dose. * The previous clinical trials is ≥30 days prior to screening; Under the circumstance of previous clinical trials≤3 months , the pre-trial drug cannot interfere the safety and efficacy of current trial judged by the investigators. * Age ≥18 years old when signing ICF, male, weight ≥50kg. * Screening ECOG performance status is ≤2. * Written information consent provided prior to the initiation of study procedures with cooperation during the follow-up.
Exclusion criteria
* Treatment requirement of Olaparib with the confirmed BRCA gene mutation. * Rechallenge of docetaxel or other chemotherapy. * Imminent Radiotherapy with radium-223. * Plan to participate in other clinical trials. * Pathological long bone fracture (cortical erosion \> 50% on imaging) or spinal cord compression. * History of other malignancies in the past 5 years with the exception of the following：cancer disease free≥5 years or squamous or basal cell skin carcinoma. * Systemic therapy of immunosuppressive agents (such as cyclosporine, tacrolimus, rapamycin, and azathioprine, etc.) within one month prior to screening. * Use of oral, intramuscular or intravenous corticosteroids within 28 days prior to enrollment. Short-term use of corticosteroids are allowed to prevent reactions for imaging studies. Use of inhaled corticosteroids for breathing insufficiency (chronic obstructive pulmonary disease) and topical steroids are allowed. * Positive infectious disease screening. Active HBV hepatitis (defined as positive HBsAg with HBV-DNA ≥ upper limit of normal （ULN））; Active hepatitis C (defined as HBV-Ab ≥ULN)； Positive COVID-19；Human immunodeficiency virus (HIV) infection with HIV-Ab ≥ULN；Positive syphilis with TP-Ab≥ULN. * Myocardial infarction, unstable angina pectoris, cardiac surgery or interventional therapy within 6 months prior to enrollment. Congestive heart failure, atrial fibrillation or other poorly controlled arrhythmias. * Cerebrovascular events (including hemorrhagic, ischemic, transient ischemic attack), craniocerebral surgery and unexplained loss of consciousness occurred within 6 months before enrollment. * Presence of the malignant pleural effusion or malignant ascites. * History of severe allergic reactions or allergies to the ingredients of Prodencel. * Abnormal screening hematologic function: white blood cell count (WBC)\<3.0×109/L, neutrophil count (NEUT)\<1.5×10\^9/L, platelet count (PLT)\<100×10\^9/L, hemoglobin (Hb)\< 100g/L. * Abnormal screening coagulation function: prothrombin time (PT) ≥ULN, international normalized ratio (INR) ≥ULN, thrombin time (TT) ≥ULN. * Abnormal screening liver and kidney function: total bilirubin (TBIL) \> 1.5ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5ULN; serum creatinine (SCr) \> 1.5 ULN. * History of splenectomy. * Presence of primary or secondary immunodeficiency disease. * History of uncontrolled seizures, central nervous system disorders, or psychotic loss of cognition. * History of chronic alcohol or drug abuse within 6 months prior to screening. * Unstable systemic diseases, such as active infection, liver cirrhosis, chronic renal failure, severe chronic lung diseases, etc. * Clinically severe pericardial effusion. * Not suitable for leukapheresis. * For any other reasons, the patients are believed not suitable for participation in this study by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (AEs) during Induction Immunization | Up to 2 weeks after the third administration | AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (AEs) during Booster Immunization | Up to approximately 1 year | AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Countries
China
Contacts
Primary ContactGuoyou Chen, Ph.D.
Backup ContactYingming Jiang, Ph.D.
Outcome results
None listed